NEW YORK, NY / ACCESSWIRE / November 27, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
PT Shareholders Click Here: https://www.zlk.com/pslra-1/pintec-technology-holdings-limited-loss-form?prid=11251&wire=1
CACC Shareholders Click Here: https://www.zlk.com/pslra-1/credit-acceptance-corporation-loss-submission-form?prid=11251&wire=1
ICPT Shareholders Click Here: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11251&wire=1
* ADDITIONAL INFORMATION BELOW *
Pintec Technology Holdings Limited (NASDAQ:PT)
This lawsuit is on behalf of shareholders who purchased PT securities pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's October 2018 initial public offering.
Lead Plaintiff Deadline : November 30, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/pintec-technology-holdings-limited-loss-form?prid=11251&wire=1
According to the filed complaint, (1) the Company erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) there were material weaknesses in Pintec's internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) as a result of the foregoing, the Company's financial results for fiscal 2017 and 2018 had been misstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Credit Acceptance Corporation (NASDAQ:CACC)
CACC Lawsuit on behalf of: investors who purchased November 1, 2019 - August 28, 2020
Lead Plaintiff Deadline : December 1, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/credit-acceptance-corporation-loss-submission-form?prid=11251&wire=1
According to the filed complaint, during the class period, Credit Acceptance Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was topping off the pools of loans that they packaged and securitized with higher-risk loans; (ii) Credit Acceptance was making high-interest subprime auto loans to borrowers that the Company knew borrowers would be unable to repay; (iii) the borrowers were subject to hidden finance charges, resulting in loans exceeding the usury rate ceiling mandated by state law; (iv) Credit Acceptance took excessive and illegal measures to collect debt from defaulted borrowers; (v) as a result, the Company was likely to face regulatory scrutiny and possible penalties from various regulators or lawsuits; and (vi) that, as a result of the foregoing, Defendants positive statements about the Company's business, operations, and adherence to appropriate laws and regulations were materially misleading and/or lacked a reasonable basis.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
ICPT Lawsuit on behalf of: investors who purchased September 28, 2019 - October 7, 2020
Lead Plaintiff Deadline : January 4, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=11251&wire=1
According to the filed complaint, during the class period, Intercept Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: